Pull to refresh
Logo
KKR agrees to take medtech supplier Integer Holdings private

KKR agrees to take medtech supplier Integer Holdings private

Money Moves

A $5.7 billion all-cash deal pulls a major maker of heart- and nerve-device parts off public markets.

5 days ago: KKR agrees to buy Integer for $5.7 billion

Overview

Integer Holdings builds the parts that go inside pacemakers, defibrillators, and nerve-stimulation devices. On August 3, the private-equity firm KKR agreed to buy the whole company for about $5.7 billion and pull it off the public market.

Integer is one of the largest contract manufacturers in medical technology, supplying Abbott, Boston Scientific, and Medtronic. Shareholders get $127 a share in cash, a 52% premium to the price before the company put itself up for review. If the deal closes by year-end, a critical supplier leaves public markets and moves under private ownership.

Why it matters

A company that makes parts inside heart and nerve devices for Abbott, Boston Scientific, and Medtronic will now answer to private-equity owners.

Questions about this story

No questions yet — be the first to ask.

Key Indicators

$5.7B
Enterprise value
Total value of the all-cash deal, including debt.
$127
Price per share
Cash paid for each Integer share.
52%
Premium
Over the share price the day before Integer's strategic review.
$796B
KKR assets
KKR's assets under management at the end of the second quarter of 2026.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 4 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Organizations Involved

Timeline

May 2023 August 2026

4 events Latest: 5 days ago
Tap a bar to jump to that date
  1. KKR agrees to buy Integer for $5.7 billion

    Latest M&A

    KKR will pay $127 a share in cash, a 52% premium to Integer's price before the review. The deal is set to close by the end of 2026.

  2. Integer opens a strategic review

    Corporate

    The company announces a review to weigh its options after what it calls strong interest. The move puts Integer in play.

  3. Payman Khales takes over as CEO

    Leadership

    Khales, the company's first chief operating officer, replaces the retiring Joseph Dziedzic and joins the board.

  4. KKR's Envision Healthcare files for bankruptcy

    Context

    KKR's $9.9 billion healthcare buyout collapses into Chapter 11, costing the firm about $5 billion. It frames the risk in KKR's healthcare deals.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

June 2018 - May 2023

KKR buys Envision Healthcare (2018-2023)

KKR bought physician-staffing company Envision Healthcare in 2018 for $9.9 billion, including debt. Envision staffed emergency rooms and billed patients directly. A 2020 federal law against surprise medical bills gutted that model.

Then

Envision filed for Chapter 11 bankruptcy in May 2023 with roughly $7 billion in debt. Lenders took over the assets.

Now

KKR lost about $5 billion, one of its biggest healthcare failures.

Why this matters now

Integer is a healthcare bet too, but a different kind. It sells parts to device makers instead of billing patients, so it avoids the payment-reform risk that sank Envision.

February-December 2024

Novo Holdings buys Catalent (2024)

Novo Holdings agreed to buy Catalent, a contract manufacturer for drugmakers, for $16.5 billion. The deal took a critical supplier private and closed in December 2024.

Then

Catalent left public markets and became a private supplier feeding the pharma industry, including Novo's own weight-loss drugs.

Now

It showed strong buyer appetite for the outsourced manufacturers that big drug and device companies depend on.

Why this matters now

Like Catalent, Integer is a behind-the-scenes maker that others rely on. Both deals pull that kind of supplier off public markets and under a single owner.

June 2021

Medline leveraged buyout (2021)

Blackstone, Carlyle, and Hellman & Friedman bought medical-supply maker Medline in a deal worth about $34 billion including debt. It was the largest healthcare buyout in years.

Then

Medline stayed private and kept supplying hospitals with gloves, gowns, and other basics.

Now

The deal showed how far private equity had moved into the medical supply chain.

Why this matters now

Integer, like Medline, is a supplier rather than a brand patients recognize. The buyout continues private equity's push into the plumbing of healthcare.

Sources

(6)